In Cephalon Case, FTC Hopes For High Court Ruling

By Sara Stefanini

Law360, New York (May 01, 2008, 12:00 AM ET) -- Despite its recent failure to challenge “pay for delay” settlements between generic-drug makers and brand-name-drug makers in court, the U.S. Federal Trade Commission has indicated its intent to continue to fight such deals, most recently pursuing a widely watched monopolization claim against Cephalon Inc. that could lead to a battle in the U.S. Supreme Court and push Congress to take action.

The FTC confirmed its continued attention to these pay-for-delay, or reverse payment, settlements — in which a brand-name company agrees to pay the generics company...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles